Swaroop Vakkalanka
- Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disordersBy Kasiviswanath Routhu, Meyyappan Muthuppalaniappan, Gayatriswaroop Merikapudi, Kanthikiran Varanasi, Sridhar Veeraraghavan, Srikant Viswanadha and Swaroop VakkalankaKasiviswanath Routhu1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaMeyyappan Muthuppalaniappan2Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaGayatriswaroop Merikapudi2Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaKanthikiran Varanasi3Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan3Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka4General Administration, Incozen Therapeutics Pvt. Ltd., Hyderabad, India
- Late-breaking abstract: Pre-clinical efficacy of RP5090 in PI3Kδ mediated airway disordersBy Kasiviswanath Routhu, Kanthikiran Varanasi, Sridhar Veeraraghavan, Meyyappan Muthuppalaniappan, G. Babu, Srikant Viswanadha and Swaroop VakkalankaKasiviswanath Routhu1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaKanthikiran Varanasi2Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan2Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaMeyyappan Muthuppalaniappan3Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaG. Babu3Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka4General Administration, Incozen Therapeutics Pvt. Ltd., Hyderabad, India
- In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K δ/γ inhibitor, in pulmonary disease systemsBy Swaroop Vakkalanka, Kasiviswanath Routhu, G. Babu, Sridhar Veeraraghavan and Srikant ViswanadhaSwaroop Vakkalanka1General Administration, Rhizen Pharmaceuticals SA, La Chaux de Fonds, SwitzerlandKasiviswanath Routhu2Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaG. Babu3Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan4Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha5Drug Discovery, Incozen Therapeutics Pvt. Ltd., Hyderabad, India
- Pre-clinical evaluation of a novel and selective PI3K δ/γ inhibitor in pulmonary fibrosisBy Kasiviswanath Routhu, Babu Govindrajulu, Sridhar Veeraraghavan, Srikant Viswanadha and Swaroop VakkalankaKasiviswanath Routhu1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaBabu Govindrajulu2Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan3Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka4General Administration, Rhizen Pharmaceuticals SA., La Chaux-de-Fonds, Switzerland
- RP6503, a novel and selective PI3K δ/γ inhibitor, potentiates the effect of steroids in pre-clinical models of COPDBy Kasiviswanath Routhu, Babu Govindrajulu, Sridhar Veeraraghavan, Srikant Viswanadha and Swaroop VakkalankaKasiviswanath Routhu2Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaBabu Govindrajulu1Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan3Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha2Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka4General Administration, Rhizen Pharmaceuticals SA., La Chaux-de-Fonds, Switzerland
- CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigsBy Kasiviswanath Routhu, Babu Govindrajulu, Sridhar Veeraraghavan, Srikant Viswanadha and Swaroop VakkalankaKasiviswanath Routhu1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaBabu Govindrajulu2Medicinal Chemistry, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSridhar Veeraraghavan3Pharmacokinetics, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSrikant Viswanadha1Pharmacology, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka4General Administration, Incozen Therapeutics Pvt. Ltd., Hyderabad, India
- LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K δ/γ inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patientsBy Javier Milara, Adela Serrano, Julio Cortijo, Srikant Viswanadha and Swaroop VakkalankaJavier Milara1Department of Pharmacology, University of Valencia, Valencia, SpainAdela Serrano2Research Foundation, University General Hospital of Valencia, Valencia, SpainJulio Cortijo3Respiratory Diseases, CIBERES, Valencia, SpainSrikant Viswanadha4Drug Discovery, Incozen Therapeutics Pvt. Ltd., Hyderabad, IndiaSwaroop Vakkalanka5Drug Development, Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
